Guillain-Barré Syndrome after COVID-19 vaccination
Until October 12th 2022, the Netherlands Pharmacovigilance Centre Lareb received 72 reports of Guillain-Barré Syndrome (GBS) following COVID-19 vaccination. GBS is labeled as a ra ...
Read more
10 MAR
Propylthiouracil and ANCA vasculitis
The Netherlands Pharmacovigilance Centre Lareb received seven well-documented reports on propylthiouracil and anti-neutrophil cytoplasmic antibody (ANCA) positive vasculitis.
Prop ...
Read more
15 FEB
Call for abstracts for the ISoP Mid-Year Symposium 2023
This year the ISoP mid-year meeting will be hosted by the Netherlands Pharmacovigilance Centre Lareb on 1-2 June 2023 in Leiden, the Netherlands. This meeting will focus on connect ...
Read more
13 FEB
Higher probability of experiencing a side effect in women after COVID-19 vaccination
Females have a two-fold higher odds of experiencing an adverse event following immunization (AEFI) than males after a COVID-19 vaccination. This difference was greater after the fi ...
Read more
07 FEB
Triage individual case safety reports using prediction model
The number of Individual Case Safety Reports (ICSRs) in pharmacovigilance databases are rapidly increasing world-wide. New methods are required to support scientific assessors in ...
Read more
13 DEC
Side effects of Tea Tree Oil
The World Health Organization (WHO) received 159 reports of complaints associated with the use of tea tree oil products. Skin complaints such as rash, hypersensitivity and redness ...
